This Week in Cardiology Podcast Por Medscape arte de portada

This Week in Cardiology

This Week in Cardiology

De: Medscape
Escúchala gratis

This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.Copyright 2019, Medscape Ciencia Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Sep 19 2025 This Week in Cardiology

    Sep 19 2025 This Week in Cardiology
    Sep 19 2025

    More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I PARACHUTE HF

    First Evidence of Treatment Benefit in Chagas Heart Failure

    https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem

    • PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021

    II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial

    Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q

    • DAPA ACT HF-TIMI 68

    https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575

    III AMALFI Trial of AF Screening

    Remote ECG Screening Ups Atrial Fibrillation Detection ‘Modestly’ https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx

    • AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482
    • STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext
    • LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link

    IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy

    • Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090
    • Variations in Rates of Stroke Across Patients With AF https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net
    Más Menos
    34 m
  • Sep 12 2025 This Week in Cardiology

    Sep 12 2025 This Week in Cardiology
    Sep 12 2025

    More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I New European Valvular Heart Disease Guidelines

    • 2025 ESC/EACTS Guidelines for the management of valvular heart disease https://doi.org/10.1093/eurheartj/ehaf194
    • Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/
    • Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528
    • Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336

    II New Drug for Resistant HTN

    • Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7
    • Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109
    • Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440

    III HCM News at ESC

    • New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv
    • MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654
    • SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424
    • ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927

    IV Vericiguat at ESC

    • New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9
    • VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4
    • VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928
    • An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4

    V More on Digoxin

    • RATE AF substudy https://doi.org/10.1002/ejhf.70022
    • Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407
    • Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net
    Más Menos
    31 m
  • Sep 05 2025 This Week in Cardiology

    Sep 05 2025 This Week in Cardiology
    Sep 5 2025

    The big beta-blocker story from ESC, dual pathway therapy with aspirin and OAC, stopping OAC after successful AF ablation, and DANCAVAS II trial are the topics John Mandrola, MD, discusses on this week's podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I Listener Feedback

    This Week in Cardiology Podcast – August 29 https://www.medscape.com/viewarticle/1002877

    II The Big Beta-blocker Story from ESC

    Beta-Blockers Post-MI: A Clear Clinical Message https://www.medscape.com/viewarticle/beta-blockers-post-mi-clear-clinical-message-2025a1000mz0

    • REBOOT https://www.nejm.org/doi/full/10.1056/NEJMoa2504735
    • BETAMI-DANBLOCK https://www.nejm.org/doi/abs/10.1056/NEJMoa2505985
    • REDUCE AMI https://www.nejm.org/doi/10.1056/NEJMoa2401479
    • CAPITAL RCT https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347
    • Post Hoc Analysis From REBOOT Trial https://eurointervention.pcronline.com/article/effect-of-beta-blocker-withholding-or-withdrawal-after-myocardial-infarction-without-reduced-ejection-fraction-on-ischaemic-events-a-post-hoc-analysis-from-the-reboot-trial
    • Beta-Blockers After MI With Mildly Reduced Ejection Fraction https://doi.org/10.1016/S0140-6736(25)01592-2
    • CAPRICORN 10.1016/S0140-6736(00)04560-8 External Link
    • BHAT https://jamanetwork.com/journals/jama/fullarticle/370103
    • ISIS 1 https://pubmed.ncbi.nlm.nih.gov/2873379/

    III Aspirin and OAC Combination Clearly Dangerous

    Aspirin Plus Oral Anticoagulants Raises Mortality, Bleeding https://www.medscape.com/viewarticle/aspirin-plus-oral-anticoagulants-raises-mortality-bleeding-2025a1000nam

    • AQUATIC https://www.nejm.org/doi/full/10.1056/NEJMoa2507532
    • AFIRE https://www.nejm.org/doi/full/10.1056/NEJMoa1904143
    • EPIC CAD https://www.nejm.org/doi/10.1056/NEJMoa2407362
    • OAC-ALONE https://pubmed.ncbi.nlm.nih.gov/30586700/

    IV Stop or Continue OAC after Successful AF Ablation

    • ALONE-AF https://jamanetwork.com/journals/jama/fullarticle/2838294
    • OCEAN trial protocol https://doi.org/10.1016/j.ahj.2017.12.007

    V DANCAVAS II Trial

    • DANCAVAS II https://doi.org/10.1093/eurheartj/ehaf704
    • DANCAVAS I https://www.nejm.org/doi/full/10.1056/NEJMoa2208681

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net
    Más Menos
    38 m
Todas las estrellas
Más relevante
Dr Mandrola delivers excellent updates on recent publications. The podcast is just the thing for a commute: not too superficial, not too detailed, and do a great job placing the new clinical advances in the context of contemporary practice.

recommend to colleagues

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
As a former Cardiology PA now working on the academic side of medicine, I’ve been out of practice for several years. Preparing to teach a cardiology course at a new program, I started brushing up on material—and stumbled across Dr. Mandrola’s podcast. Wow. I wish I had known about this resource back when I was still practicing clinically.

In just a short time, I’ve learned what’s new since I left practice, and even picked up on things I probably should have known better back then. More importantly, I’ve gained an entirely new appreciation for how to critically review clinical trials and recognize bias.

What sets this podcast apart is Dr. Mandrola’s humility and honesty: his willingness to point out flaws in studies, to admit when he doesn’t know something, and to change his perspective when the evidence supports it. That kind of intellectual honesty builds trust, and it makes him feel less like a distant expert and more like a fellow learner walking through the field with you.

I’ve flown through the last two years of episodes in just a week, and I’m looking forward to being a dedicated listener moving forward. Thank you, Dr. Mandrola, for approaching cardiology not as a lecture, but as a thoughtful, ongoing conversation.

Honest, Insightful, and Incredibly Valuable

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
I absolutely love listening to this podcast and feel I practice medicine very similarly. I love your critical review of studies as it brings these areas to light. I especially loved your comment at the end of this podcast discussing the reasoning to go into EP. I agree with your reasons, and consider them the same for most fields of medicine, especially any in cardiology, which I practice as a PA in and have for 14 years. Going into medicine just for the money should never be the reason as it will only lead to frustration and burnout. Thank you for your honest reviews and feedback each week.

EP is not about the money -love this statement

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.
Me gusta el escepticismo del Dr Mandrola. Habla de su objetividad y su compromiso con la ciencia bien hecha

Muy informativo

Se ha producido un error. Vuelve a intentarlo dentro de unos minutos.